Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute Joins IGN to Provide Sequencing Sample-Prep Services

Premium

This story was originally published Feb. 16.

The Broad Institute has joined the Illumina Genome Network and will offer its proprietary sample preparation processes for human whole-genome sequencing, Illumina said last week.

The IGN is Illumina's human whole-genome sequencing services business, and offers human whole-genome sequencing for customers through its own services lab and through partnerships with other institutes that have been certified to provide sequencing services on its instruments.

The Broad will offer sample-prep processes that enable sequencing of "challenging low input" DNA less than 500 nanograms and also from formalin-fixed, paraffin-embedded samples.

The Broad and Illumina will jointly evaluate projects to determine their suitability for the services.

"The Broad Institute's innovative sample preparation methods provide researchers with the ability to sequence samples that were previously inaccessible with existing techniques," Christian Henry, Illumina's vice president and general manager of the genomic solutions business unit, said in a statement.

Other members of the IGN include the BC Cancer Agency's Michael Smith Genome Sciences Centre, the University of Washington Department of Genome Sciences, the National Center for Genome Resources in New Mexico, the Macrogen/Genomic Medicine Institute in Korea, and Illumina's own services lab.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.